Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:
  • Active, not recruiting  
  • « Prev · Page 23

NCT ID: NCT00057395 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid Malignancies

Start date: n/a
Phase: Phase 1/Phase 2
Study type: Interventional

To determine the rate of response and the duration of the response following therapy with Aroplatinin patients with advanced solid malignancies.

NCT ID: NCT00054951 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads

Start date: June 2001
Phase: Phase 1/Phase 2
Study type: Interventional

MTC-DOX is Doxorubicin or DOX, a chemotherapy drug, that is adsorbed, or made to “stick,” to magnetic beads (MTCs). MTCs are tiny, microscopic particles of iron and carbon. When DOX is added to MTCs, DOX attaches to the carbon part of the MTCs. MTC-DOX is directed to and deposited in the area of a tumor, where it is thought that it then “leaks” through the blood vessel walls. Once in the surrounding tissues, it is thought that Doxorubicin becomes “free from” the magnetic beads and will then be able to act against the tumor cells. The iron component of the particle has magnetic properties making it possible to direct MTC-DOX to specific tumor sites in the liver by placing a magnet on the body surface. It is hoped that MTC-DOX used with the magnet may target the chemotherapy directly to liver tumors and provide a treatment to patients with liver cancer. Patients enrolled in the study will be administered MTC-DOX through a hepatic artery catheter inserted under radiological guidance. During and following injection of the MTC-DOX, the drug will be localized to the hepatic tumor site by use of an external magnet. Dose may be divided in order to localize MTC-DOX to all lesions. The MTC-DOX intrahepatic infusions will be repeated every three weeks until tumor progression, complete remission, unacceptable toxicity, or a maximum of six treatment cycles. The purpose of this Phase 1/2 study is to evaluate time to disease progression following administration of MTC-DOX.

NCT ID: NCT00043433 Active, not recruiting - Clinical trials for Hepatocellular Carcinoma

Study of T900607-Sodium in Chemotherapy Naive Patients With Hepatocellular Carcinoma.

Start date: July 2002
Phase: Phase 2
Study type: Interventional

The purpose of the study is to determine whether T900607-sodium is effective and safe in treating hepatocellular carcinoma, a type of liver cancer.

NCT ID: NCT00027768 Active, not recruiting - Liver Cancer Clinical Trials

Radioactive Iodine in Treating Patients Who Have Undergone Surgery for Liver Cancer

Start date: June 2001
Phase: Phase 3
Study type: Interventional

RATIONALE: Radioactive iodine may be effective in reducing the rate of recurrence of liver cancer after surgery to remove the tumor. It is not yet known if radioactive iodine is more effective than no further treatment after surgery. PURPOSE: Randomized phase III trial to determine the effectiveness of radioactive iodine in treating patients who have undergone surgery for liver cancer.